Funding has been awarded to principal investigator Dr. Melissa Mugambi by the Bill and Melinda Gates Foundation for "Evaluating and optimizing a virtual care model for PrEP delivery."
Abstract:
Dr. Mugambi will partner with an e-pharmacy and an implementing organization in Kenya to jointly develop and evaluate an end-to-end platform to support a client to initiate and continue PrEP through a virtual care model. The specific PrEP products to be delivered through this platform include TDF/FTC daily oral PrEP and Dapivirine Ring, with consideration to support the delivery of a monthly oral formulation after 2024 if Islatravir proves safe and efficacious in phase 3 trial.
